Exelixis and Daiichi Sankyo's Minnebro (Esaxerenone) Receives MHLW Marketing Approval In Patients With Hypertension In Japan
Shots:
- The approval is based on P-III ESAX-HTN study assessing esaxerenone vs eplerenone for 12wks. in patients with essential hypertension- 1EP as SBP / DBP
- In 2006- Exelixis and Daiichi Sankyo collaborated to develop and commercialize and Esaxerenone tablets. Exelixis will receive $20M milestone on sales and has received additional $20M as on regulatory milestones in Q1’18
- Minnebro tablets (1.25/2.5/5 mg) are antihypertensives drug used for blocking mineralocorticoid receptor activation and is evaluated in P-III for diabetic nephropathy by Daiichi
Ref: Exelixis | Image: Daiichi Sankyo
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com